11.06.2013 - Bill Gates and EU Research Commissioner Máire Geoghegan-Quinn have signed a partnership to fight neglected diseases.
The multibillion partnership of the Bill & Melinda Gates Foundation and the European Commission aims at fighting and other poverty-related diseases such as HIV/AIDS, tuberculosis malaria, lymphatic filariasis or sleeping sickness, which affect more than one billion people globally. "The foundation is completely committed to supporting efforts to develop life-saving products to help solve some of the world’s toughest problems“, said Gates. The partnership will develop at least one improved product per year, according to Geoghegan-Quinn.
Much of the work will be carried out through the European and Developing Countries Clinical Trials Partnership (EDCTP), which so far involves 16 European and 30 sub-Saharan African countries. The European Commission has proposed funding of up to €1 bn from the EU budget to match the contributions of the European partner countries.
Between 2007 and 2011, Gates and the EU invested around €2.4bn in R&D on neglected infectious diseases. Under the agreement, the partners will develop new drugs, vaccines and diagnostics suited to the needs of the population of poor countries , improve health systems and ensure the delivery of such products. Furthermore, the Gates Foundation and the Commission will launch a joint innovation prize in 2014 in order to honour current approaches to global health.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more